Wednesday, August 13, 2025
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Medicine

UT Health San Antonio to lead $11 million, NIH-funded study of a first-ever oral chlamydia vaccine

May 9, 2024
in Medicine
Reading Time: 4 mins read
0
UT Health San Antonio to lead $11 million, NIH-funded study of a first-ever oral chlamydia vaccine
65
SHARES
592
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT

SAN ANTONIO, May 9, 2024 – The study of a novel oral vaccine that could protect against chlamydia infection has been awarded approximately $11 million in National Institutes of Health funding over five years through a cooperative agreements research project grant, known as a U01 grant.

SAN ANTONIO, May 9, 2024 – The study of a novel oral vaccine that could protect against chlamydia infection has been awarded approximately $11 million in National Institutes of Health funding over five years through a cooperative agreements research project grant, known as a U01 grant.

ADVERTISEMENT

“We are excited about receiving the U01 award because it will enable us to move our basic microbiology and immunology bench research work closer to developing a medically significant reagent for ‘making human lives better,’ our institution’s overall mission,” said Guangming Zhong, MD, PhD, professor of microbiology, immunology and molecular genetics with the Joe R. and Teresa Lozano Long School of Medicine at The University of Texas Health Science Center at San Antonio (UT Health San Antonio), and principal investigator of the study.

Chlamydia is the most reported sexually transmitted disease and affects about 4 million people in the United States each year, according to the Centers for Disease Control and Prevention. And yet, while there are vaccines for other sexually transmitted infections including HPV, hepatitis A and hepatitis B, there is none for chlamydia.

The infection often is left untreated due to the lack of specific symptoms. Untreated chlamydial infections can lead to severe complications including pelvic inflammatory disease, infertility and ectopic pregnancy.

Zhong said the prospective vaccine, called intrOv, came about after several years of persistent effort studying chlamydial pathogenic mechanisms in mice.

While investigating mouse-adapted chlamydia, the team accidently found that genital chlamydia that spread to the gastrointestinal tract established long-standing colonization.

From there, they tried an oral inoculation of chlamydia to the GI system and found that it became not only non-pathogenic but also offered protective immunity against subsequent infection in other tissues including the genital tract and airways.

This surprising finding, Zhong said, led them to conclude that an oral delivery of chlamydia could serve as a vaccination against the infection. The team then created mutant versions of the infection that could no longer cause disease but could induce transmucosal protection.

One of these attenuated mutants, intrOv, included unique qualities viable for cross-species translation to the human pathogen of chlamydia.

“Since the human pathogen chlamydia has more than 15 serotypes, developing a vaccine against all 15 serotypes is challenging,” Zhong said. “Using the mouse-adapted, chlamydia-bases vaccine intrOv to cover all 15 serotypes is a nice surprise.”

This grant supports the production of investigative new drug-enabling data for moving the oral chlamydia vaccine to Phase I trials.

“We will optimize the immunization regimens, identify protection immune correlates in mouse models and validate the vaccine efficacy in pigs and non-human primates,” Zhong said.

If all goes well at that stage, the team will file an Investigational New Drug, or IND, application with the Food and Drug Administration to advance the vaccine to clinical trials by the end of the grant’s time frame.

Back in 2022, UT Health San Antonio was granted an exclusive global license to allow Ohio biopharmaceutical company Blue Water Vaccines Inc. to develop Zhong’s findings into an oral vaccine for chlamydia.

Study collaborators from the Department of Microbiology, Immunology and Molecular Genetics at UT Health San Antonio include Zhenming “Jack” Xu, PhD, and Nu Zhang, PhD, who will provide B cell and T cell expertise.

Other collaborators include Pat Frost, DVM, and Marie-Claire Gauduin, PhD, primate genital-tract infection experts with Texas Biomedical Research Institute; Yufeng Wang, PhD, bioinformatics expert with The University of Texas at San Antonio; Luis M de la Maza, MD, PhD, with the University of California at Irvine; Huizhou Fan, MD, PhD, with Rutgers University; Harlan Caldwell, PhD, chief of chlamydial diseases section at the National Institute of Allergy and Infectious Diseases, NIAID; Robert Brunham, MD, with the University of British Columbia; and William Geisler, MD, MPH, from the University of Alabama.


 

The University of Texas Health Science Center at San Antonio (UT Health San Antonio), a primary driver of San Antonio’s $44.1 billion health care and biosciences sector, is the largest academic research institution in South Texas with an annual research portfolio of $413 million. Driving substantial economic impact with its six professional schools, a diverse workforce of more than 8,500, an annual expense budget of $1.46 billion and clinical practices that provide 2.6 million patient visits each year, UT Health San Antonio plans to add more than 1,500 higher-wage jobs over the next five years to serve San Antonio, Bexar County and South Texas. To learn about the many ways “We make lives better®,” visit UTHealthSA.org.

Stay connected with The University of Texas Health Science Center at San Antonio on Facebook, Twitter, LinkedIn, Instagram and YouTube.

 

 

 



Share26Tweet16
Previous Post

Rensselaer researcher finds that users seek out echo chambers on social media

Next Post

Staffordshire and NUST universities launch Creative AI Lab

Related Posts

blank
Medicine

Author Correction: New Analysis Clarifies Parkinson’s Trial Benefits

August 13, 2025
blank
Medicine

Micromovement Analysis and Reaction Times Offer New Insights into Predicting Alcohol Relapse After Treatment

August 13, 2025
blank
Medicine

Genomic Origins of Chaetognath’s Unique Body Plan

August 13, 2025
blank
Medicine

Integrating Oncology and Primary Care Coordination Essential for Optimal Cancer Patient Outcomes

August 13, 2025
blank
Medicine

3D Structure of Active and Silent E. coli

August 13, 2025
blank
Medicine

AI-Driven Knowledge Graphs Illuminate Mental Health Exploration

August 13, 2025
Next Post
Staffordshire University's Virtual Production Studio

Staffordshire and NUST universities launch Creative AI Lab

  • Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27533 shares
    Share 11010 Tweet 6881
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    947 shares
    Share 379 Tweet 237
  • Bee body mass, pathogens and local climate influence heat tolerance

    641 shares
    Share 256 Tweet 160
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    507 shares
    Share 203 Tweet 127
  • Warm seawater speeding up melting of ‘Doomsday Glacier,’ scientists warn

    310 shares
    Share 124 Tweet 78
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • Author Correction: New Analysis Clarifies Parkinson’s Trial Benefits
  • Optimizing Fuel Cell Parameters with AI Techniques
  • Episodic Reservoir Flooding: Sediment Sources and Global Impacts
  • Transforming Unripe Fruits into Specialty Coffees Through Innovative Fermentation Techniques

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 4,859 other subscribers

© 2025 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2025 Scienmag - Science Magazine

Discover more from Science

Subscribe now to keep reading and get access to the full archive.

Continue reading